Leman Biotech Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Investors
-
12
Leman Biotech General Information
Description
Developer of immunotherapies for metabolic cancer designed to treat solid tumors. The company utilizes immunometabolic reprogramming and artificial intelligence to develop metabolic enhanced car-t cells, IL-10-Fc fusion proteins, tumor-infiltrating lymphocytes, interleukin-10 mutants, biological macromolecular drugs, and immune cell drugs, thereby enabling healthcare providers to improve immune cell function and enhance therapeutic responsiveness in oncology applications.
Contact Information
Website
www.lemanbio.comCorporate Office
- Futian International Biomedical Industrial Park
- Number 1 Haihong Road, Futian District
- Shenzhen, Guangdong
- China
Corporate Office
- Futian International Biomedical Industrial Park
- Number 1 Haihong Road, Futian District
- Shenzhen, Guangdong
- China
Leman Biotech Timeline
Leman Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Early Stage VC | 07-Jul-2026 | Completed | Generating Revenue | |||
| 9. Early Stage VC (Series A) | 04-Mar-2026 | Completed | Generating Revenue | |||
| 8. Early Stage VC | 28-Feb-2026 | Completed | Generating Revenue | |||
| 7. Early Stage VC | 27-Apr-2025 | Completed | Generating Revenue | |||
| 6. Secondary Transaction - Private | 27-Apr-2025 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 12-Nov-2024 | Completed | Generating Revenue | |||
| 4. Early Stage VC | 29-May-2024 | Completed | Generating Revenue | |||
| 3. Grant | 19-Apr-2024 | Completed | Generating Revenue | |||
| 2. Secondary Transaction - Private | 31-Oct-2022 | $15.7M | Completed | Generating Revenue | ||
| 1. Seed Round | 18-Jan-2022 | $15.7M | $15.7M | Completed | Startup |
Leman Biotech Comparisons
Industry
Financing
Details
Leman Biotech Competitors (1)
One of Leman Biotech’s competitors is JW Therapeutics, a Formerly VC-backed company based in Shanghai, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| JW Therapeutics | Formerly VC-backed | Shanghai, China |
Leman Biotech Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Shanghai Guofang Private Equity Fund Management | Growth/Expansion | Minority | ||
| Guangdong Yuecai Zhongyin Private Equity Investment Fund Management | PE/Buyout | Minority | ||
| Guangdong Yuecai Venture Capital | Growth/Expansion | Minority | ||
| Hangzhou Tailong Venture Capital Partnership | Growth/Expansion | Minority | ||
| Zhongshan Financial Investment | Venture Capital | Minority |
Leman Biotech FAQs
-
When was Leman Biotech founded?
Leman Biotech was founded in 2021.
-
Where is Leman Biotech headquartered?
Leman Biotech is headquartered in Shenzhen, China.
-
What industry is Leman Biotech in?
Leman Biotech’s primary industry is Drug Discovery.
-
Is Leman Biotech a private or public company?
Leman Biotech is a Private company.
-
What is Leman Biotech’s current revenue?
The current revenue for Leman Biotech is .
-
How much funding has Leman Biotech raised over time?
Leman Biotech has raised $58.7M.
-
Who are Leman Biotech’s investors?
Shanghai Guofang Private Equity Fund Management, Guangdong Yuecai Zhongyin Private Equity Investment Fund Management, Guangdong Yuecai Venture Capital, Hangzhou Tailong Venture Capital Partnership, and Zhongshan Financial Investment are 5 of 12 investors who have invested in Leman Biotech.
-
Who are Leman Biotech’s competitors?
JW Therapeutics is a competitor of Leman Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process